Volume 31, Number 1—January 2025
Online Report
Research and Development of Medical Countermeasures for Emerging Infectious Diseases, China, 1990–2022
Figure 2

Figure 2. Pipeline of medical countermeasures for emerging infectious diseases by developer type, R&D type, and regulatory pathway, China, 1990–2022. Partnership indicates that the candidate was jointly developed by >2 developers. Responsive and proactive R&D were differentiated on the basis of the time between the occurrence of disease in China and the earliest R&D of candidate. A) Distribution of medical countermeasures by developer type and countermeasure type. B) Distribution of medical countermeasures by R&D type. C) Distribution of medical countermeasures by regulatory pathway. MP, Major Program of National Science and Technology; PR, Priority Review; R&D, research and development; SER, Special Examination Review.